Co-Diagnostics, Inc. filed a Form 8-K on November 19, 2026, disclosing that its board approved a 1-for-25 reverse stock split of its common stock, effective 12:01 a.m. Mountain Time on November 24, 2026, following stockholder approval at a November 13, 2026 special meeting.

Key Highlights

  • Reverse split ratio: The board approved a 1-for-25 ratio, meaning every 25 issued and outstanding shares of common stock will be combined into one share.
  • Effective date: The Articles of Amendment were filed with the Utah Division of Corporations and Commercial Code on November 19, 2026, effective 12:01 a.m. Mountain Time on November 24, 2026.
  • Post-split share count: Immediately after the reverse stock split becomes effective, there will be approximately 521,779 shares of common stock issued and outstanding, according to the filing.
  • No fractional shares: Stockholders who would otherwise receive a fractional share will instead receive one whole share of common stock.
  • New CUSIP number: The common shares will trade under new CUSIP number 189763 303, effective November 24, 2026, and will continue under the symbol "CODX."
  • Stockholder authorization: Stockholders approved at the November 13, 2026 special meeting a range of not less than 1-for-2, with a cumulative maximum of 1-for-750, with the final ratio determined by the board.

Co-Diagnostics Files 1-for-25 Reverse Split Amendment with Utah

According to the Form 8-K filed with the SEC on November 19, 2026, Co-Diagnostics, Inc. (NASDAQ:CODX) disclosed that its board of directors approved a 1-for-25 reverse stock split ratio on November 13, 2026, the same day stockholders voted at a special meeting to authorize such a split. The Articles of Amendment to the Company's Articles of Incorporation were filed with the Utah Division of Corporations and Commercial Code on November 19, 2026. Trading on a split-adjusted basis on The Nasdaq Capital Market is set to begin at market open on November 24, 2026.

The filing states that the reverse stock split will not modify the rights or preferences of the common stock, and will not change the number of shares of capital stock authorized for issuance under the Company's Articles of Incorporation. All stock options and warrants outstanding immediately prior to the reverse stock split will be proportionally adjusted in accordance with their respective terms. The Company disclosed it will not issue fractional shares; instead, each stockholder entitled to a fractional share will receive one whole share in lieu of that fraction.

The Company has appointed VStock Transfer, LLC as exchange agent for the reverse stock split, according to the filing. Stockholders holding shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split and, the filing states, "will not be required to take further action in connection with the reverse stock split, subject to brokers' particular processes." The Company also issued a press release on November 19, 2026, announcing the reverse stock split, furnished as Exhibit 99.1 to the filing.

What Was Disclosed

Co-Diagnostics filed an 8-K on November 19, 2026, announcing a board-approved 1-for-25 reverse stock split of its common stock, effective November 24, 2026, resulting in approximately 521,779 shares outstanding and a new CUSIP number, with the ticker symbol "CODX" remaining unchanged.